Nature CommunicationsNeurosciencePeer-reviewed journal article
Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers
Abstract
Oligomeric forms of amyloid-{beta} (A{beta}) peptide are known to be the primary neurotoxic species in Alzheimers disease (AD), but how they interact with neurons to produce their deleterious effects is unclear. Over ten different cell-surface receptors for A{beta} have been described, but their molecular interactions with A{beta} assemblies and their relative contributions to mediating AD pathology have remained uncertain. In the present work, we have used super-resolution microscopy to directly visualize A{beta}-receptor interactions at the nanometer scale. We report that one documented A{beta} receptor, the cellular prion protein, PrPC, specifically inhibits the polymerization A{beta} fibrils via a unique mechanism in which it binds specifically to the rapidly growing end of each fibril, thereby blocking polarized elongation at that end. PrPC binds neurotoxic oligomers and protofibrils in a similar fashion, suggesting that it may recognize a common, end-specific, structural motif on all of these assemblies. Finally, two other candidate A{beta} receptors, Fc{gamma}RIIb and LilrB2, affect A{beta} fibril growth in a manner similar to PrPC. Taken together, our results suggest that neurotoxic signaling by several different receptors may be activated by common molecular interactions with both fibrillar and oligomeric A{beta} ligands. Targeting such interactions with small molecules represents an attractive therapeutic strategy for treatment of AD.
- Citations
- 55
- FWCI
- 5.49
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimers Disease Brain
Mikhail A. Kostylev, Carmen Butan, … Stephen M. Strittmatter·Nature CommunicationsPeer-reviewed·Jul 22, 2026
- Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies
Johanne M Kaplan, Ebrima Gibbs, … Neil R. Cashman·Alzheimer s & Dementia Translational Research & Clinical InterventionsPeer-reviewed·Oct 1, 2025
- Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Arun Upadhyay, Deepak Chhangani, … Jeffrey N. Savas·Molecular NeurodegenerationPeer-reviewed·Sep 14, 2023
- Antibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Sarah M. Ruttenberg, Rakia Dhaoui, … James S. Nowick·PLoS ONEPeer-reviewed·Sep 8, 2025
- Impact of cellular prion protein expression on disease progression and pathology in two mouse models of Alzheimer's disease
Silvia A. Purro, Michael Farmer, … John Collinge·bioRxiv·Sep 25, 2022
- p21-activated kinase regulates Rab3a vesicles to repair plasma membrane damage caused by Amyloid-β oligomers
Deepak Kunhi Valappil, Priyadarshini Veerabhadraswamy, … Sangeeta Nath·Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseasePeer-reviewed·Dec 24, 2025